Review
Medicine, General & Internal
Yuxian Lin, Xiaowei Zheng, Qiujie Chen, Ruibin Wu
Summary: This study aims to evaluate the clinical efficacy of anti-VEGF therapy versus PRP for patients with PDR through a meta-analysis, providing a reliable theoretical basis for future research.
Article
Multidisciplinary Sciences
Jipeng Li, Aman Chandra, Lin Liu, Lin Zhang, Jun Xu, Meng Zhao
Summary: This study investigated the influence of impaired renal function on fundus characteristics, pars-plana vitrectomy (PPV) details, and outcomes in patients with proliferative diabetic retinopathy (PDR). The results showed that impaired renal function was related to hypertension, incomplete pan-retinal photocoagulation, severe fibrovascular membrane, and extensive retinal vascular closure. Patients with impaired renal function had a higher occurrence of intraoperative bleeding and a higher percentage of intraocular subretinal fluid drainage. However, there was no significant difference in visual acuity improvement between patients with and without impaired renal function.
Review
Medicine, General & Internal
Liangyu Wang, Zhaoli Chen, Xiaoxue Wang
Summary: This study aimed to compare the efficacy and acceptability of PRP with intravitreal conbercept injections versus PRP alone for patients with PDR. Systematic review and meta-analysis methods were used to search for relevant cohort studies and analyze the data.
Review
Endocrinology & Metabolism
Xiao Xie, Chao Lian, Zhiping Zhang, Meng Feng, Wenqi Wang, Xiaomeng Yuan, Yanmei Shi, Tingting Liu
Summary: This meta-analysis compared the long-term efficacy and safety of intravitreal aflibercept injection (IAI) for diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). The results showed that IAI treatment group had better visual acuity improvement and central subfield thickness reduction compared to other treatment groups.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Ophthalmology
Varun Chaudhary, Gurkaran S. Sarohia, Mark R. Phillips, Daniel Park, Jim Xie, Dena Zeraatkar, Matthew Fung, Lehana Thabane, Anat Loewenstein, Frank G. Holz, Sunir J. Garg, Peter K. Kaiser, Mohit Bhandari, Robyn H. Guymer, Samantha Fraser-Bell, Sobha Sivaprasad, Charles C. Wykoff
Summary: This systematic review and meta-analysis examined the effectiveness of anti-vascular endothelial growth factor (VEGF) treatment in managing eyes with non-proliferative diabetic retinopathy (NPDR) without centre involving diabetic macular oedema (CI-DMO). The findings suggest that aflibercept treatment can reduce the risk of vision-threatening complications (VTCs) and lead to regression of diabetic retinopathy severity score (DRSS) in NPDR eyes without CI-DMO over a period of 2 years.
Review
Ophthalmology
Matteo Fallico, Andrea Maugeri, Andrew Lotery, Antonio Longo, Vincenza Bonfiglio, Andrea Russo, Teresio Avitabile, Alfredo Pulvirenti, Claudio Furino, Gilda Cennamo, Martina Barchitta, Antonella Agodi, Michele Reibaldi
Summary: The study found that anti-vascular endothelial growth factor (VEGF) therapy may be associated with better visual outcomes, while panretinal photocoagulation (PRP) and anti-VEGF treatment alone or in combination with PRP showed comparable efficacy in terms of neovascularization regression.
ACTA OPHTHALMOLOGICA
(2021)
Review
Endocrinology & Metabolism
Wuyue Zhang, Jinsong Geng, Aimin Sang
Summary: Combining PRP with anti-VEGF treatment in DR patients can significantly improve BCVA and NV regression without increasing the incidence of adverse events, proving the efficacy and safety of this combination therapy as a management strategy for DR.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Jinfeng Qu, Xiuju Chen, Qinghuai Liu, Fang Wang, Mingxin Li, Qiong Zhou, Jin Yao, Xiaoxin Li
Summary: This study aimed to evaluate the effects of preoperative intravitreal aflibercept (IVA) injection on the incidence of postoperative vitreous hemorrhage (VH) in patients with proliferative diabetic retinopathy (PDR). The results showed that the VH incidence was significantly lower in the IVA group compared to the control group, and it also improved visual acuity. Therefore, prophylactic use of aflibercept can reduce the risk of postoperative hemorrhage in patients with PDR.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Endocrinology & Metabolism
Yaoyao Sun, Huijun Qi
Summary: This study compared the therapeutic effects of intravitreal Conbercept plus panretinal photocoagulation (PRP) to PRP monotherapy in patients with high-risk proliferative diabetic retinopathy (PDR). The results showed that the IVC+PRP group had a higher rate of neovascularization (NV) regression, better improvement in best-corrected visual acuity (BCVA), and a lower vitrectomy rate compared to the PRP monotherapy group. Additionally, the IVC+PRP group had a lower number of laser spots and lower central macular thickness (CMT) compared to the PRP group.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Multidisciplinary Sciences
Kiyoung Kim, Eung Suk Kim, Seung-Young Yu
Summary: This study evaluated the quantitative changes in microvascular parameters after panretinal photocoagulation in diabetic retinopathy using swept-source OCT Angiography. The results showed significant longitudinal retinal microvascular changes after PRP, with overall macular perfusion status gradually recovering over 12 months. Additionally, early treatment responses in PD can predict the long-term outcomes of PDR after PRP.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Maria H. Berrocal, Luis Acaba-Berrocal, Alexandra M. Acaba
Summary: The long-term outcomes of pars plana vitrectomy (PPV) for complications of proliferative diabetic retinopathy were evaluated. The results showed that eyes that underwent PPV had better visual outcomes than eyes that received conventional treatment, regardless of age group.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Endocrinology & Metabolism
Gordon S. Crabtree, Jonathan S. Chang
Summary: Diabetes can result in severe visual loss due to various mechanisms, but advances in treatment including anti-VEGF medications and modern surgical techniques have led to improved outcomes for patients with diabetic retinopathy. Further research is needed to determine the most effective delivery method and timing for treatment.
CURRENT DIABETES REPORTS
(2021)
Review
Medicine, General & Internal
Yao Hu, Jinxia Shen, Yi Peng
Summary: This study aims to systematically review level I evidence in the literature to determine whether intravitreal aflibercept injection can provide better vision restoration compared with vitrectomy with panretinal photocoagulation for proliferative diabetic retinopathy patients. The study design follows PRISMA guidelines and evaluates outcomes including change in best-corrected visual acuity, area of neovascularization, and area of retinal nonperfusion, with results reported strictly according to PRISMA criteria.
Article
Ophthalmology
E. E. Cornish, S. Wickremasinghe, H. Mehta, L. Lim, S. S. Sandhu, V. Nguyen, M. C. Gillies, S. Fraser-Bell
Summary: The study aimed to determine whether targeted retinal laser photocoagulation (TPRP) to peripheral retinal ischaemia reduces the number of aflibercept injections needed for treating diabetic macular oedema (DMO) over a 24-month period. The results showed that combination therapy of laser and aflibercept did not reduce the overall burden of aflibercept injections.
Article
Endocrinology & Metabolism
Mingwei Si, Yuan Tao, Ziniu Zhang, Hui Zhao, Wenxuan Cui, Mengyao Yang, Hong Wang
Summary: This study aimed to observe and compare retinal vein diameter changes and other essential indicators in patients with high-risk proliferative diabetic retinopathy (PDR) treated with intravitreal injection of conbercept (IVC) combined with panretinal photocoagulation (PRP) versus PRP monotherapy. The results showed that IVC+PRP therapy has a significant advantage over PRP monotherapy in the treatment of high-risk PDR, as it can reverse diabetes-induced retinal vein changes and restore morphology and function.
FRONTIERS IN ENDOCRINOLOGY
(2023)